Company News

November 11, 2013
Back to TopE-mailPrintBookmark and Share

Shares of Endocyte Inc. came roaring back after the company’s executives finally convinced investors there’s a real possibility of getting European approval in the next two months for its first drug. Shares of West Lafayette-based Endocyte soared by nearly 41 percent from its close on Tuesday, just before the company issued its pipeline update, until the end of the week, when the shares closed at $11.64 apiece. Endocyte executives said they expect European regulators to render a decision on its ovarian cancer drug, vintafolide, in December or January. The European regulators have requested an oral presentation by Endocyte, which is usually a sign of some controvery, Wall Street analysts noted. If Endocyte gets the green light, it would start working with its partner, New Jersey-based Merck & Co. Inc., to sell vintalofide next year. Endocyte is also seeking approval for a companion imaging agent. Combined, analysts expect the two products could bring Endoycte as much as $200 million in revenue by 2018.

Two former Eli Lilly and Co. scientists accused of stealing the drugmaker’s trade secrets and passing them to a Chinese company have been released to a halfway house by a federal judge in Indianapolis. The judge, William Lawrence, also acknowledged that the men’s attorneys had “poked sufficient holes” in the case brought by U.S. Attorney Joe Hogsett against the men by suggesting that Guoqing Cao and Shuyu “Dan” Li, only passed on information that Lilly had already put into the public domain. Cao and Li, both of whom live in Carmel, were arrested in October for allegedly emailing sensitive information about nine of Lilly’s experimental drug programs to an employee of Jiangsu Hengrui Medicine Co. Ltd., which is based in China. An executive of Indianapolis-based Lilly estimated during a court hearing that the trade secrets were worth at least $55 million.

Paragon Medical Inc., a Pierceton, Ind.,-based supplier to orthopedic implant companies, has agreed to be acquired by Chicago-based private equity firm Beecken Petty O'Keefe & Co. Financial terms of the transaction, which is expected to close in December, were not disclosed. The company has 950 employees, according to its website.

Testosterone replacement drugs, including one made by Eli Lilly and Co., raised the risk of heart, attack, stroke or death by 29 percent, according to a study of 8,700 men released last week. According to Bloomberg News, the study is the first of a class of drugs, which includes Lilly’s Axiron, as well as AbbVie Inc.’s Androgel. Indianapolis-based Lilly is expected to achieve $168 million in sales this year from Axiron. Androgel could achieve $1.1 billion in sales, according to figures compiled by Bloomberg. An earlier study of testosterone supplements used in elderly males, funded by the U.S. National Institute on Aging and run at Boston Medical Center, was stopped in 2009 because an audit found it caused more heart attacks and high blood pressure. Teresa Shewman, a Lilly spokeswoman, said the company is aware of cardiovascular events in men taking testosterone therapies. “Lilly works with the scientific community and regulatory bodies to further understand and communicate the risks and benefits of testosterone replacement therapy,” Shewman said. “As a company responsible for developing medicines, Lilly is committed to providing advertising that is truthful, accurate and balanced.”


Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. OK Larry, let's sign Lance, shore up the PG and let's get to the finals.

  2. A couple of issues need some clarification especially since my name was on the list. I am not sure how this information was obtained and from where. For me, the amount was incorrect to begin with and the money does not come to me personally. I am guessing that the names listed are the Principal Investigators (individual responsible for the conduct of the trail) for the different pharmaceutical trials and not the entity which receives the checks. In my case, I participate in Phase II and Phase III trials which are required for new drug development. Your article should differentiate the amount of money received for consulting, for speaking fees, and for conduct of a clinical trial for new drug development. The lumping of all of these categories may give the reader a false impression of physicians just trying to get rich. The Sunshine Law may help to differentiate these categories in the future. The public should be aware that the Clinical Trial Industry could be a real economic driver for Indiana since these revenues supports jobs and new job creation. Nationally, this account for 10-20 billion which our State is missing out on to a large degree. Yes, new drug and technology development has gotten most of the attention (e.g. CTSI, BioCrossroads, etc.) However, serious money is being left on the table by not participating in the clinical trials to get those new drugs and medical devices on the market!!!! I guess that this is not sexy enough for academia.

  3. The address given for the Goldfish Swim Club is the Ace Hardware, is it closing?

  4. Out of state management and ownership. If Kite controlled it, everything would be leased. Of course, due to the roundabout, there is limited access to the south side of 116th now also. Just have to go down to the light.

  5. Hey smudge, You're opposed to arresting people for minor crimes? Sounds great! We should only focus on murders and such, right? Let's stand around and wait until someone shoots someone before we act. Whatever we do, we should never question anyone, frisk anyone, or arrest anyone unless they are actively engaged in shooting or stabbing. Very sound!